De Santis M, Palou Redorta J, Nishiyama H, Krawczynski M, et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial. Lancet 2025 Oct 17:S0140-6736(25)01897-5. doi: 10.1016/S0140-6736(25)01897.
PMID: 41115436